Cyclosporin A.
Cyclosporin A is a new immunosuppressive agent that selectively affects T helper cells without suppressing the bone marrow. Cyclosporin A has been used primarily to prevent rejection in organ transplantation and acute graft-versus-host disease. Studies suggest that it may be of benefit in psoriasis, pemphigus vulgaris, bullous pemphigoid, Behçet's disease, and collagen vascular disorders. Since cyclosporin A has a potentially important use in dermatology, and since a number of dermatologic side effects are seen as a consequence of its use, it is important that dermatologists be familiar with this drug.
D001528:Behcet Syndrome / Q000188:drug therapy; D003095:Collagen Diseases / Q000188:drug therapy; D003524:Cyclosporins / Q000009:adverse effects / Q000627:therapeutic use*; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D005886:Gingival Hypertrophy / Q000139:chemically induced; D006084:Graft Rejection / Q000187:drug effects; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007674:Kidney Diseases / Q000139:chemically induced; D009182:Mycosis Fungoides / Q000188:drug therapy; D009422:Nervous System Diseases / Q000139:chemically induced; D010391:Pemphigoid, Bullous / Q000188:drug therapy; D010392:Pemphigus / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy; D012751:Sezary Syndrome / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy*; D014605:Uveitis / Q000188:drug therapy
D003524:Cyclosporins